Medingo deal?
This article was originally published in The Gray Sheet
Executive Summary
Developer of the Solo miniature insulin dispensing patch pump, which is 92% owned by diversified conglomerate Elron, could be sold for up to $213 million, including milestone payments, based on a "non-binding indication of interest" from an un-named third party, Elron says Oct. 26. But a Medingo deal would be subject to signing of a definitive agreement, and currently "there is no assurance of the occurrence, timing or terms of any such transaction," the firm says
You may also be interested in...
Roche Acquires Insulin Patch Pump Maker Medingo For Up To $200 Mil.
Firm is ramping up production for expected 2012 launch of the Solo pump.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.